Fate Therapeutics, Inc. FATE
2.35
0.02
0.86%
as of 25 Sep
- Market cap
- $279.2M
- P/E
- 0.0×
Follow FATE
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
21.01 | 17.52 | 22.81 | 50.08 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(6.15) | (4.99) | (4.67) | (13.87) | |
P/B ratio |
0.64 | 0.56 | 0.80 | 2.12 | |
Price to Tangible BV |
0.64 | 0.56 | 0.80 | 2.12 | |
EV/Sales |
5.53 | 2.66 | 11.74 | 42.56 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.36) | (0.17) | (0.72) | (2.71) | |
EV/FCF |
(0.34) | (0.16) | (0.69) | (2.62) | |
Quick Ratio |
7.69 | 5.67 | 5.72 | 4.74 | |
Current Ratio |
7.87 | 5.79 | 5.85 | 4.85 | |
Net Debt/EBITDA |
6.67 | 6.26 | 5.67 | 5.28 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.02 | 0.02 | 0.02 | 0.02 | |
Operating CF/Net income |
0.76 | 0.72 | 0.99 | 0.78 | |
Capex/Depreciation |
(0.91) | (0.44) | (0.11) | (0.04) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,484.09% | 1,857.20% | 1,901.69% | 1,171.33% | |
Selling, General and Administrative Expense of Revenue |
611.03% | 779.04% | 738.72% | 424.06% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
279.21% | 403.80% | 302.46% | 168.97% | |
Graham Net Nets |
0.74 | 0.83 | 0.52 | 0.16 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(104.76%) | (117.35%) | (90.83%) | (38.89%) | |
Free Cash Flow Yield |
(76.90%) | (95.93%) | (74.79%) | (32.43%) | |
Revenue per Share |
0.01 | 0.01 | 0.01 | 0.02 | |
Operating CF per Share |
(0.20) | (0.20) | (0.26) | (0.19) | |
Capex per Share |
(0.02) | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.22) | (0.20) | (0.26) | (0.20) | |
Cash per Share |
1.81 | 1.71 | 1.46 | 1.28 | |
Shareholders Equity per Share |
1.97 | 1.74 | 1.50 | 1.27 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.97 | 1.74 | 1.50 | 1.27 | |
Free Cash Flow |
(26.57) | (24.27) | (31.06) | (23.51) | |
Working Capital |
193.14 | 172.63 | 148.84 | 125.36 | |
Capital Expenditures |
(2.20) | (0.95) | (0.24) | (0.08) | |
Net Current Asset Value |
111.65 | 96.95 | 74.32 | 51.29 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
1.26 | 0.70 | 0.18 | 0.04 | |
Net Profit Margin |
(1,852.38%) | (2,364.79%) | (2,402.85%) | (1,448.56%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.40 | 2.23 | 1.56 | 1.05 | |
Average Payables |
4.93 | 6.01 | 3.73 | 3.65 | |
Average Assets |
419.32 | 379.82 | 341.79 | 315.87 | |
Average Common Equity |
298.19 | 262.95 | 234.06 | 207.40 |
Columns are period end dates